Literature DB >> 6101544

Molecular pathology of schizophrenia: more than one disease process?

T J Crow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6101544      PMCID： PMC1600263          DOI： 10.1136/bmj.280.6207.66

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  33 in total

1.  Pneumoencephalographic studies in mental disease.

Authors:  J O HAUG
Journal:  Acta Psychiatr Scand Suppl       Date:  1962

2.  A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS.

Authors:  D W Woolley; E Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  1954-04       Impact factor: 11.205

3.  Reduced monoamine oxidase activity in blood platelets from schizophrenic patients.

Authors:  D L Murphy; R J Wyatt
Journal:  Nature       Date:  1972-07-28       Impact factor: 49.962

4.  Brain dopamine and behaviour. A critical analysis of the relationship between dopamine antagonism and therapeutic efficacy of neuroleptic drugs.

Authors:  T J Crow; C Gillbe
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

5.  Stereotyped activities produced by amphetamine in several animal species and man.

Authors:  A Randrup; I Munkvad
Journal:  Psychopharmacologia       Date:  1967

6.  Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine.

Authors:  C Kornetsky
Journal:  Arch Gen Psychiatry       Date:  1976-12

7.  Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication.

Authors:  P M Cotes; T J Crow; E C Johnstone; W Bartlett; R C Bourne
Journal:  Psychol Med       Date:  1978-11       Impact factor: 7.723

8.  Possible virus in schizophrenia and some neurological disorders.

Authors:  D A Tyrrell; R P Parry; T J Crow; E Johnstone; I N Ferrier
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

9.  Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.

Authors:  E C Johnstone; T J Crow; C D Frith; M W Carney; J S Price
Journal:  Lancet       Date:  1978-04-22       Impact factor: 79.321

10.  Increased dopamine-receptor sensitivity in schizophrenia.

Authors:  F Owen; A J Cross; T J Crow; A Longden; M Poulter; G J Riley
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321
View more
  140 in total

Review 1.  Functional brain mapping of psychopathology.

Authors:  G D Honey; P C Fletcher; E T Bullmore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 2.  Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning.

Authors:  B E Seaton; G Goldstein; D N Allen
Journal:  Neuropsychol Rev       Date:  2001-03       Impact factor: 7.444

3.  Correction of apathic-abulic manifestations of the processual defect by cholinotropic preparations.

Authors:  A V Golenkov; V O Lukin
Journal:  Neurosci Behav Physiol       Date:  1992 May-Jun

4.  System impact and methodological issues in the development of an empirical typology of psychiatric hospital residents.

Authors:  E J Holohean; S M Banks; B A Maddy
Journal:  J Ment Health Adm       Date:  1995

5.  Starting again with clinical research.

Authors:  T J Crow
Journal:  BMJ       Date:  1991-03-02

Review 6.  Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Authors:  William R Keller; Bernard A Fischer; William T Carpenter
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

Review 7.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

8.  Automated classification of fMRI during cognitive control identifies more severely disorganized subjects with schizophrenia.

Authors:  Jong H Yoon; Danh V Nguyen; Lindsey M McVay; Paul Deramo; Michael J Minzenberg; J Daniel Ragland; Tara Niendham; Marjorie Solomon; Cameron S Carter
Journal:  Schizophr Res       Date:  2012-01-25       Impact factor: 4.939

9.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

10.  Amphetamine response and relapse risk after depot neuroleptic discontinuation.

Authors:  B Angrist; E Peselow; M Rubinstein; A Wolkin; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.